by admin | Mar 10, 2026 | English
Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromes Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT...
by admin | Aug 27, 2025 | English
Zemcelpro® is conditionally authorized by the European Commission for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is...
by admin | Jun 19, 2025 | English
– If approved, Zemcelpro® is expected to: increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromes be the first and only therapy in the...
by admin | Jun 4, 2024 | English
– UM171 Cell Therapy has been granted an International Nonproprietary Name (INN) of “dorocubicel” on the INN Recommended List issued by the World Health Organization (WHO) – The U.S. Food and Drug Administration (FDA) has granted UM171 Cell Therapy...
